Drugs / Rupatifen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07711262 | Aug 2026 → Oct 2027 expected | seasonal allergic rhinitis | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rupatifen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07711262 ↗ |
| Route | Oral | “Oral administration” NCT07711262 ↗ |